GRIFOLS’ RED-FACED SHAREHOLDERS FINALLY SEE SOME GREENER PASTURES (BUY; 34% UPSIDE)
19/01/23 -" Amidst the volatile markets of the past two years, while Big Pharmas have materially outperformed – thereby regaining their safe-haven status - Smaller Pharmas have been out of favour due to both ..."
Pages
55
Language
English
Published on
19/01/23
You may also be interested by these reports :
26/07/24
The Q2 results came in ahead of expectations, driven by a strong showing across most target areas. As we had indicated the possibility earlier, the ...
26/07/24
The Q2 results beat the market’s expectations, driven by the robust momentum for Dupixent, the healthy trajectory for new launches, and strong growth ...
26/07/24
The outlook has improved, though challenges remain. The company initially lost credibility after announcing a weak 2024 outlook back in the autumn of ...
25/07/24
The Q2 results came in ahead of expectations, with healthy growth witnessed across the targeted areas. Consequently, the management revised its ...